诺华同意以120亿美元收购美国创新药公司Avidity

Core Viewpoint - Novartis has agreed to acquire Avidity Biosciences for $72 per share in cash, representing a 46% premium, with a total transaction value of $12 billion. This acquisition is expected to stimulate further mergers and acquisitions in the pharmaceutical industry [1] Group 1 - The acquisition price of $72 per share indicates a significant premium of 46% over Avidity's current market value [1] - The total value of the transaction is estimated at $12 billion, highlighting the scale of the deal within the biotech sector [1] - Avidity is developing experimental drugs for rare diseases, including treatments for neuromuscular diseases, which aligns with Novartis's strategic focus on innovative therapies [1]